Get started
Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

AMLX trade ideas

AMLX - Pre Catalyst Run up Play with massive GAP!Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder. Shares float: 61.87M Topline Data 16/10/2024 ET Phase 2 topline data to be presented at ISPAD October 16-19, 2024. Phase 2 first patient dosed April 13, 2023. Phase 2 enrollment completed, noted February 8, 2024. Phase 2 data demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression, noted April 10, 2024. 2 more catalysts end of August 2025 and end of December 2025 Huge down gap from $18.00 to $4.50 Breakout and Entry Zone above: $2.60 Action: If the stock breaks above this area with strong volume, it might signal a continuation of the upward trend. Overall Market Sentiment: Currently, the market seems to be in a correction phase. It’s crucial to consider this sentiment when making trading decisions. Resistance Points: $3.00 $3.90 $4.50 $6.50 $8.50 $10.00 $11.50 $13.00 $15.50 Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains. Trading Strategy: Take Profit (TP): Set a target at $6.50 (pre catalyst run up) and if we see a full gap fill set a second one at $18.00 (highly speculative and could take time) Stop Loss (SL): Set at under $1.70 to mitigate potential losses. Chart Analysis: Please refer to the attached chart for detailed analysis of price trends and movements. Trading Advisory: Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities. Disclaimer: This content is for informational purposes only and should not be considered financial advice.
NASDAQ:AMLXLong
by meitshels_smell_trades
1
Insiders loading - BIG GAP FILL POTENTIAL - AMLX - BIOTECH PLAYInsiders high level are loading up shares in the sub 3.00 area, I will personally scoop up shares between 2.99-2.54 Below that this plan is invalid. Stop placed at 2.54. HUGE POTENTIAL FOR GAP FILL ON ANY POSITIVE NEWS. GOING THROUGH NO MANS LAND WITH VOLUME MEANS HUGE POTENTAL. Because these things can be event based set your limit sells at numbers that make sense for you. I will be cutting 35% around 4.30-4.40. Might buy back if it drops to 3.80s before any gap filling takes place. Looking at a 43% upside from these levels to recent highs and if a bullish event-based volume day happens... Well, 6.51 is the next stop, and possibly $11. Not a bad risk/reward ratio here. Maybe the insiders, CFOs directors know something we don't just yet.
NASDAQ:AMLXLong
by mortimerkylej
2
break out?The stock has shown a reversal from its downtrend and is currently in an uptrend. The price has broken through previous resistance levels, indicating potential for further gains if it holds above the resistance turned support. Potential Scenarios: Bullish Continuation: If the price sustains above the $2.40 resistance level, it could act as a new support level, potentially leading to further upside. Look for confirmation through continued high volume and maintaining RSI within acceptable limits without significant pullbacks. Pullback: Given the sharp increase and high RSI, a short-term pullback to test the new support at $2.40 is possible. If the price holds at $2.40, it could present a buying opportunity for further gains. Reversal: If the price fails to hold above $2.40 and falls back below this level, it might indicate a false breakout and potential return to lower support levels, such as around $1.60 or lower. Conclusion: Monitor the stock for continued strength above $2.40. Watch for any signs of reversal or pullback, especially if the RSI remains in overbought territory. Ensure that any new positions are taken with proper risk management, considering potential volatility.
NASDAQ:AMLX
by jaudio2017
Amylyx Stock Down With Over 82%, After Pivotal ALS Drug FailureAmylyx stock ( NASDAQ:AMLX ) crashed Friday, losing almost all of its value, after the company said its approved ALS treatment, Relyvrio, failed in a pivotal study. Patients who received Amylyx Pharmaceuticals' ( NASDAQ:AMLX ) Relyvrio showed no significant difference across multiple markers measuring the severity of amyotrophic lateral sclerosis, the longhand name for ALS. In this disease, nerve cells break down, reducing muscle function. The Food and Drug Administration approved Relyvrio based on a single study in September 2022. But Amylyx ( NASDAQ:AMLX ) continued on with a Phase 3 study. Now, Amylyx ( NASDAQ:AMLX ) is deciding whether to voluntarily pull the drug from the market in the U.S. and Canada. In Canada, it sells under the brand name Albrioza. Technical Analysis On today's stock market, Amylyx ( NASDAQ:AMLX ) stock plummeted 82.9% to 3.36. Shares undercut their 50-day and 200-day moving averages, MarketSurge.com shows. That put shares at a record low. Way Forward For Amylyx Stock? It's important to note that Relyvrio failed to make a difference across multiple measures, including the key goal of the study: improvement on the revised Amyotrophic Lateral Sclerosis Functional Rating Scale. The company tested Relyvrio over 48 weeks. Secondary measures of the study also flopped. Amylyx ( NASDAQ:AMLX ) says it now expects to have the results of its study in Wolfram syndrome patients in the second quarter.
NASDAQ:AMLXShort
by DEXWireNews
AMLX ANALYSISAmylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA. Gross margin TTM -20,475.44% Operating margin TTM -41,275.09% Net Profit margin TTM -42,545.96% Return on Investment TTM -78.45% Period Ending: Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Dec 31, 2020 Total Revenue 0 0 0.28 0.35 Gross Profit Operating Income -47.81 -28.32 -54.37 -8.59 Net Income -47.85 -28.34 -59.59 -8.59 Name Company PE Industry PE P/E Ratio TTM -10.84 23.39 Price to Sales TTM 4,610.78 7 Price to Cash Flow MRQ - 51.31 Price to Free Cash Flow TTM -12.7 56.76 Price to Book MRQ 5.45 9.41 Price to Tangible Book MRQ 5.44 102.93 Return on Equity TTM -100.65% 35.69 Return on Equity 5YA -100.65% 28.09 Return on Assets TTM 0% 11.42 Return on Assets 5YA -146.9% 8.98 Return on Investment TTM-78.45% 16.7 Return on Investment 5YA-113.25% 13.93 MY SOURCE: INVESTING.COM do u think this pump was done by early investors who were thick n thin to regain their losses n pull the plug on unisightful investors or will a miracle drug be produced and change the tides all i know is its always going to be profit over humanity funny considering how profit is derived from humanity My interest will begin at 16.70 and 15. 40 as to wether some miracle will happen or wether it will kaput SENNA SEASON
NASDAQ:AMLX
by Bekiumuzi_Dube